Volume 16 - Issue 11 - November, 2004

Reversible Pulmonary Hypertension in a Patient Treated with Protacylcin

Untreated pulmonary hypertension is a relentlessly progressive disorder leading to death from right ventricular failure, regardless of etiology. In recent years, more effective medical therapy has become available for this condition. In particular, intravenous prostacyclin has been shown to improve symptoms, exercise tolerance, and prognosis in pulmonary arterial hypertension.1
Among the many drawbacks of intravenous prostacyclin is the usual requirement for permanent continuation of therapy. Patients started on this agent are advised that it is very unlikely that it will ever be s



Primary PCI Without On-site Surgery and Without On-site Cath Lab

Modern treatment of acute myocardial infarction is based on early and complete reperfusion. The time between the onset of myocardial infarction and reperfusion determines the mortality benefit and is influenced by various factors including a large delay in seeking medical attention by the patients.1 The best strategy for reperfusion has been an area of ongoing research. Emergency primary percutanoeus intervention (PCI) is superior to thrombolysis in selected cases.2 To make early primary PCI available to a wider population, various strategies, including PCI in catheteriza



Adjunctive Therapy for Cardiovascular Intervention — Its Time Has Come

It is with great excitement that The Journal of Invasive Cardiology will be initiating a new section called “Adjunctive Therapy.” While much of the focus of cardiovascular intervention relies upon mechanical approaches to improve perfusion, it has become clear in recent years that adjunctive pharmacotherapy is critical to improve upon the results obtained by mechanical means alone. Specific examples include the introduction of the intravenous glycoprotein IIb/IIIa inhibitors and more recently the direct thrombin inhibitor bivalirudin.1,2 Indeed, without the incorporation of dual



The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-Hospital and 30-Day Results

Peripheral arterial disease (PAD) affects 8–12 million Americans with an estimated 12–20% of the population > 65 years of age afflicted. Approximately 50% of patients are asymptomatic, which may explain why this disease is often under-diagnosed and thus under-treated.1 As the population ages and awareness increases, the prevalence of PAD will increase. PAD is associated with significant mortality and morbidity, and patients with PAD undergoing procedures are at an increased risk for ischemic and hemorrhagic events.2 Peripheral procedures are often technically more com



Primary Angioplasty Without On-site Surgical Back-up: The First Experience with Mobile Catherization Facility

Multi-center randomized trials indicate that primary angioplasty in acute myocardial infarction (AMI) lowers the rates of death, stroke, recurrent ischemia and re-infarction compared with fibrinolytic therapy.1 For low-risk patients with AMI, the mortality of primary angioplasty can be very low (< 0.5%), and hospital costs can be decreased.2 Furthermore, most AMI patients included in these studies were not candidates for fibrinolytic therapy, either because they had bleeding risks or shock, or did not have diagnostic electrocardiograms.3 These subgroups of pati



Six-Month Clinical and Angiographic Outcomes of the Tecnic Carbostent™Coronary System: The Phantom IV Study

The Tecnic Carbostent™ (Sorin Biomedica, Saluggia, Italy) is a balloon-expandable, stainless steel tubular coronary stent with a unique cellular design and proprietary Carbofilm permanent coating.1-3 Recently the stent has been pre-mounted on a new low-profile rapid-exchange delivery system. The aim of this study was to assess the procedural, in-hospital, and long-term clinical and angiographic outcomes of patients undergoing angioplasty with the new Tecnic Carbostent system for de novo coronary lesions.

Methods
Patient population. Between October 2001 and



Editor's Message (Nov. 2004)

Dear Readers,

This issue of The Journal of Invasive Cardiology, which coincides with the American Heart Association Annual Scientific Sessions, includes original research articles, case reports, reviews, and articles from the journal’s special sections, Electrophysiology Corner, Clinical Images, and a new special section titled Adjunctive Therapy, edited by Dr. Deepak Bhatt from the Cleveland Clinic.

The first research article by Dr. Efthymios Deliargyris and colleagues from the Wake Forest University School of Medicine in Winston-Salem, North Carolina, features



Transradial Catheterization: The Road Less Traveled

Retrograde cannulation of a peripheral artery is a necessary step for current percutaneous coronary procedures. Since the first reported case of coronary angiography via the radial artery by Campeau in 1989, the transradial approach has been well studied. Large randomized clinical trials comparing transradial catheterization to traditional access have demonstrated advantages with respect to patient comfort, cost containment, and greatly reduced local vascular complications.2–4 In one representative study, major entry site complications were absent in the transradial group and pres



  • « Previous
  •  | Page 1 of 3 | 
  • Next »